Data on Acute Lymphoblastic Leukemia Discussed by Researchers at University of Lyon (How Much Does the Hospital Stay for Infusion of Anti-cd19 Car-t Cells Cost To the French National Health Insurance?): Oncology – Acute Lymphoblastic Leukemia

2022 JAN 06 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Daily -- Research findings on Oncology - Acute Lymphoblastic Leukemia are discussed in a new report. According to news reporting originating from Lyon, France, by NewsRx correspondents, research stated, “Chimeric antigen receptor T-cells (CAR-T cells) have the potential to be a major innovation as a new type of cancer treatment, but are associated with extremely high prices and a high level of uncertainty. This study aims to assess the cost of the hospital stay for the administration of anti-CD19 CAR-T cells in France.”

Funders for this research include SIRIC LYriCAN, Institut Convergences Plascan.

Our news editors obtained a quote from the research from the University of Lyon, “Data were collected from the French Medical Information Systems Program (PMSI) and all hospital stays associated with an administrated drug encoded 9439938 (tisagenlecleucel, Kymriah ®) or 9440456 (axicabtagene ciloleucel, Yescarta ®) between January 2019 and December 2020 were included. 485 hospital stays associated with an injection of anti-CD19 CART cells were identified, of which 44 (9%), 139 (28.7%), and 302 (62.3 %) were for tisagenlecleucel in acute lymphoblastic leukaemia (ALL), tisagenlecleucel in diffuse large B-cell lymphoma (DLBCL), and axicabtagene ciloleucel respectively. The lengths of the stays were 37.9, 23.8, and 25.9 days for tisagenlecleucel in ALL, tisagenlecleucel in DLBCL, and axicabtagene ciloleucel, respectively. The mean costs per hospital stay were (sic) 372,400 for a tisagenlecleucel in ALL, (sic) 342,903 for tisagenlecleucel in DLBCL, and (sic) 366,562 for axicabtagene ciloleucel. CAR T-cells represented more than 80 % of these costs. n = 13 hospitals performed CAR-T cell injections, with two hospitals accounting for more than 50% of the total number of injections. This study provides original data in a context of limited information regarding the costs of hospitalization for patients undergoing CAR-T cell treatments.”

According to the news editors, the research concluded: “In addition to the financial burden, distance may also be an important barrier for accessing CAR T-cell treatment.”

This research has been peer-reviewed.

For more information on this research see: How Much Does the Hospital Stay for Infusion of Anti-cd19 Car-t Cells Cost To the French National Health Insurance? Bulletin du Cancer, 2021;108(12):1170-1180. Bulletin du Cancer can be contacted at: Elsevier Masson, Corp Off, 65 Camille Desmoulins CS50083 Issy-Les-Moulineaux, 92442 Paris, France.

The news editors report that additional information may be obtained by contacting Lionel Perrier, University of Lyon, Center Leon Berard, Gate L Se Umr 5824, F-69008 Lyon, France. Additional authors for this research include Marius Huguet, Vincent Augusto, Veronique Raimond and Emmanuelle Kaltenbach.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.bulcan.2021.06.005. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)